Edwards Lifesciences officer may sell $113K in stock

Edwards Lifesciences Corp (EW) is the issuer for a Rule 144 notice filed for officer Wayne Markowitz.

Rhea-AI Filing Summary

Edwards Lifesciences Corp (EW) is the issuer for a Rule 144 notice filed for officer Wayne Markowitz. The filing covers a proposed sale of 1,240 shares of Edwards Lifesciences common stock, with an aggregate market value of $113,417.00 and 576,400,000 shares outstanding as of August 26, 2026. The shares to be sold arise from equity compensation via restricted stock lapses of 537, 111, and 592 shares on specified future dates. Over the prior three months, Markowitz reported sales of 9,628 shares for $818,958.00 and 147 shares for $12,588.00.

Key Figures

Shares to be sold: 1,240 shares of common stock Aggregate market value of shares to be sold: $113,417.00 Shares outstanding: 576,400,000 shares +5 more

8 metrics

Shares to be sold 1,240 shares of common stock Proposed Rule 144 sale by officer Wayne Markowitz

Aggregate market value of shares to be sold $113,417.00 Value of 1,240 shares covered by the Form 144 notice

Shares outstanding 576,400,000 shares Edwards Lifesciences common stock outstanding as of August 26, 2026

Recent sale on July 28, 2026 9,628 shares for $818,958.00 Reported sale by Wayne Markowitz in the prior three months

Recent sale on July 30, 2026 147 shares for $12,588.00 Additional reported sale by Wayne Markowitz in the prior three months

Restricted stock lapse tranche 537 shares Equity compensation-related shares linked to a May 7, 2025 lapse

Restricted stock lapse tranche 111 shares Equity compensation-related shares linked to a September 14, 2025 lapse

Restricted stock lapse tranche 592 shares Equity compensation-related shares linked to a May 8, 2026 lapse

Key Terms

Rule 144, Restricted Stock Lapse, Equity Compensation

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Lapse financial

"Common | 05/07/2025 | Restricted Stock Lapse | EDWARDS"

Equity Compensation financial

"537 | 05/07/2025 | Equity Compensation"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for EW disclose about planned share sales?

The Form 144 notice discloses that officer Wayne Markowitz may sell up to 1,240 shares of Edwards Lifesciences common stock with an aggregate market value of $113,417.00, in reliance on Rule 144, based on equity compensation awards.

How many Edwards Lifesciences (EW) shares did Wayne Markowitz sell in the last 3 months?

Over the past three months, Wayne Markowitz reported sales of 9,628 shares for $818,958.00 on July 28, 2026, and 147 shares for $12,588.00 on July 30, 2026.

What is the outstanding share count of Edwards Lifesciences (EW) referenced in the Form 144?

The filing references that Edwards Lifesciences had 576,400,000 shares of common stock outstanding as of August 26, 2026, providing context for the relative size of the proposed Rule 144 sale.

What is the source of the Edwards Lifesciences (EW) shares to be sold under this Form 144?

The shares are tied to equity compensation from restricted stock lapse events, including tranches of 537, 111, and 592 shares scheduled on specified dates between 2025 and 2026.

Who is the insider associated with the Form 144 for Edwards Lifesciences (EW)?

The notice is filed for Wayne Markowitz, identified as an officer of Edwards Lifesciences Corp, regarding potential sales of company common stock under Rule 144.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/26/2026 - 04:04 PM EDT Accepted by SEC EDGAR 08/26/2026 - 04:02 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001991414
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Edwards Lifesciences Corp
SEC File Number	001-15525
Address of Issuer	ONE EDWARDS WAY IRVINE CALIFORNIA 92614
Phone	9492502500
Name of Person for Whose Account the Securities are To Be Sold	Markowitz Wayne
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	1240	113417.00	576400000	08/26/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/07/2025	Restricted Stock Lapse	EDWARDS LIFESCIENCES CORPORATION			537	05/07/2025	Equity Compensation
Common	09/14/2025	Restricted Stock Lapse	EDWARDS LIFESCIENCES CORPORATION			111	09/14/2025	Equity Compensation
Common	05/08/2026	Restricted Stock Lapse	EDWARDS LIFESCIENCES CORPORATION			592	05/08/2026	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
WAYNE MARKOWITZ ONE EDWARDS WAY IRVINE CA 92614	Edwards Lifesciences Corp	07/28/2026	9628	818958.00
WAYNE MARKOWITZ ONE EDWARDS WAY IRVINE CA 92614	Edwards Lifesciences Corp	07/30/2026	147	12588.00

144: Remarks and Signature

Remarks
Date of Notice	08/26/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	WAYNE MARKOWITZ
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)